FDA approves LEMBAZ (adrabetadex) for infantile-onset Niemann-Pick disease type C after survival analysis shows a 55% lower risk of death.
Written By: Sravani Pamanji, PharmD
Reviewed By: Pharmacally Editorial Team
On November 17, 2026, the U.S. Food and Drug Administration (FDA) approved LEMBAZ™ (adrabetadex) injection to reduce the risk of death in adults and children with Niemann-Pick disease type C (NPC) weighing at least 7 kg whose neurological symptoms began before 6 years of age. The approval introduces the first FDA-approved treatment shown to improve survival in patients with infantile-onset NPC, a severe form of the inherited disorder associated with progressive neurological deterioration and premature mortality.
The decision was supported by survival findings demonstrating a 55% reduction in the risk of death among patients receiving adrabetadex compared with matched external controls, with a median overall survival of 8.5 years in the treated group versus 4.9 years in the control group.
Niemann-Pick Disease Type C: Understanding the Disease Burden
Niemann-Pick disease type C is a rare inherited lysosomal storage disorder—affecting approximately 1 in 150,000 people—caused by mutations in the NPC1 or NPC2 proteins that disrupt intracellular cholesterol and lipid trafficking. This abnormal accumulation in the brain and nervous system leads to progressive neurological impairment, including loss of motor coordination and difficulty swallowing. Patients with infantile-onset NPC (symptom onset before age 6) face a particularly rapid disease course and high risk of premature death. While two previously approved therapies, Miplyffa (arimoclomol) and Aqneursa (levacetylleucine), address neurological manifestations, neither has demonstrated a survival benefit, and their age and weight restrictions limit access for younger patients.
Clinical Evidence and Development of Adrabetadex
The FDA’s approval was anchored by a pooled overall survival analysis of 36 patients with infantile-onset NPC treated with LEMBAZ across three clinical studies and an Expanded Access Program (EAP), compared against matched external controls. Adrabetadex achieved a 55% reduction in mortality risk (median overall survival of 8.5 years vs. 4.9 years), a benefit observed regardless of background off-label miglustat therapy. While Beren Therapeutics noted that the FDA accepted the matched external-control comparison as adequate and well-controlled, these findings derive from non-randomized external comparisons and should be interpreted accordingly.
Broader clinical evaluation of adrabetadex (formerly VTS-270, 2-hydroxypropyl-β-cyclodextrin) included a Phase 2b/3 prospective, randomized, double-blind, sham-controlled, three-part study (NCT02534844) in patients with neurological manifestations of NPC1. That trial assessed intrathecal VTS-270 using the NPC Severity Scale (evaluating ambulation, cognition, fine motor skills, and swallowing) alongside clinical global assessments. Because the survival benefit reflects pooled data across three studies and the EAP, the 55% mortality risk reduction should not be attributed to this single trial alone.
Mechanism of Action and Administration
LEMBAZ is a cyclodextrin-based therapy designed to bind and mobilize accumulated cholesterol within brain cells, restoring normal intracellular lipid trafficking. It is strictly intended for intrathecal use and is administered directly into the spinal canal by a trained healthcare professional once every two weeks.
Safety Profile and Important Precautions
LEMBAZ carries a boxed warning for hearing impairment, including permanent hearing loss ranging from mild to profound, which can occur even in patients with normal baseline hearing. Consequently, comprehensive audiological evaluations are mandatory prior to initiating therapy and must be repeated throughout dose escalation and maintenance to guide dose adjustments or escalation limits.
The most common adverse reactions—occurring in at least 25% of clinical trial patients—include ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Ataxia and fatigue typically emerge within the first few days post-administration; severe episodes requiring hospitalization have been observed, particularly at higher doses, and may warrant dose reduction.
Regulatory Significance and Clinical Interpretation
Granted Breakthrough Therapy designation during development, LEMBAZ was approved for Mandos, LLC, a subsidiary of Beren Therapeutics, PBC, which also received a Rare Pediatric Disease Priority Review Voucher. By targeting underlying cholesterol-trafficking defects and demonstrating a clinically meaningful survival advantage, LEMBAZ addresses a critical unmet need in infantile-onset NPC, though its real-world impact will rely on rigorous audiological safety monitoring and patient access.
References
Beren Therapeutics Announces U.S. FDA Approval of LEMBAZ™ (adrabetadex), First & Only Medicine to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C, Beren Therapeutics, 17 November 2026
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer, US FDA, 17 November 2026
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease, ClinicalTrials.gov ID NCT02534844
FDA Approves First Treatment for Niemann-Pick Disease, Type C, US FDA, 20 September 2024
FDA Approves New Drug to Treat Niemann-Pick Disease, Type C, US FDA, 24 September 2026
About the Writer
Sravani Pamanji is a PharmD (LinkedIn) professional with experience in scientific writing, medical literature review, drug profile preparation, and clinical case documentation. She has contributed to scientific publication and presented at the 74th Indian Pharmaceutical Congress. Her training includes ICH GCP E6(R3), scientific research, and medication safety. She is passionate about evidence-based medical communication and accurate dissemination of clinical and pharmaceutical information.
